bronchial asthma (heat asthma)
Conditions
Interventions
Sponsors
China-Japan Friendship Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) Met the diagnostic criteria of Western medicine for bronchial asthma; (2) In accordance with the diagnostic criteria of TCM asthma (Heat Asthma Syndrome); (3) Chronic persistent patients with asthma control test (ACT) questionnaire score < 20; (4) The severity of the disease was mild persistent and moderate persistent; (5) The patients who did not use anti asthmatic drugs 2 weeks before the screening or those who had been treated with ICs or ICs + Laba for 4 weeks or more before enrollment, and the drug type and dose remained unchanged; (6) Aged from 18 to 65 years old; (7) Sign informed consent.
Exclusion criteria
Exclusion criteria: (1) Refractory asthma, critical asthma, occupational asthma, seasonal asthma, atypical asthma or upper and lower respiratory tract infection, pneumonia, pulmonary tuberculosis, pulmonary interstitial fibrosis, thoracic deformity, chronic obstructive pulmonary disease, bronchiectasis, cystic pulmonary fibrosis, allergic bronchiolitis, allergic granulomatous vasculitis and other special types, infectious and restrictive Pulmonary diseases and other air flow obstructive pulmonary diseases; (2) Patients with severe primary diseases of heart, brain, liver, kidney and hematopoiesis and mental illness; (3) Patients with primary immunodeficiency disease and acquired immunodeficiency syndrome; (4) People with allergic constitution and allergic to the drug ingredients in the test drug; (5) Glutamic transaminase (ALT) and aspartate aminotransferase (AST) were 1.5 times higher than the upper limit of normal value, and serum creatinine (CR) was higher than the upper limit of normal value; (6) Pregnant, lactating and pregnant women; (7) Participate in other clinical studies within one month before screening; (8) Those who are considered unsuitable to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of good asthma control; | — |
Secondary
| Measure | Time frame |
|---|---|
| Grading of asthma control level;Change value and change rate of TCM syndrome integral;The number of times / week change value of relief drug (salbutamol aerosol);Changes of asthma quality of life questionnaire (Mini AQLQ);Number of acute asthma attacks (including mild, moderate, severe and severe asthma);Peak expiratory flow (PEF) measurements and changes;Measurement and change of FEV1 and FVC before using bronchodilator; | — |
Countries
China
Contacts
Public ContactJiangtao Lin
China-Japan Friendship Hospital
Outcome results
None listed